CorMedix (CRMD) Liabilities and Shareholders Equity (2010 - 2025)

CorMedix has disclosed Liabilities and Shareholders Equity across 15 years of filings, most recently posting $826.1 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $826.1 million, up 595.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 billion (up 514.3% YoY), and the FY2025 annual result was $826.1 million, up 595.14% from the prior year.
• Liabilities and Shareholders Equity came in at $826.1 million for Q4 2025 at CorMedix, up from $750.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $826.1 million in Q4 2025 to a low of $57.0 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $76.5 million (2021), against an average of $157.9 million.
• Across the five-year window, Liabilities and Shareholders Equity fell 22.94% in 2022 and soared 867.78% in 2025, its largest moves.
• CorMedix's Liabilities and Shareholders Equity stood at $68.9 million in 2021, then fell by 10.02% to $62.0 million in 2022, then surged by 32.27% to $82.1 million in 2023, then surged by 44.83% to $118.8 million in 2024, then jumped by 595.14% to $826.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $826.1 million (Q4 2025), $750.9 million (Q3 2025), and $252.6 million (Q2 2025), per Business Quant data.